Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chengjie Ke

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Immunopharmacology and Immunotoxicology|March 23, 2026
Comprehensive Pharmacovigilance Analysis of Lebrikizumab: A Real-World Safety Assessment Based on the FDA Adverse Event Reporting System (FAERS) DatabaseMaohua Chen, Chengjie Ke, Yaping Huang
The Journal of Dermatology|July 27, 2025
Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance StudyYaping Huang, Chengjie Ke, Maohua Chen
Dermatitis : Contact, Atopic, Occupational, Drug|November 18, 2025
Disproportionality Analysis of Nemolizumab in Patients with Atopic Dermatitis: A Real-World Pharmacovigilance StudyMaohua Chen, Chengjie Ke, Yaping Huang
Diagnostic Microbiology and Infectious Disease|September 28, 2024
Herpes virus reactivation induced by abrocitinib: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseMaohua Chen, Chengjie Ke, Yaping Huang
Inflammopharmacology|February 6, 2026
Postmarketing adverse events of biologics and Janus kinase inhibitors in patients with atopic dermatitisYaping Huang, Qing Zhou, Chengjie Ke, et al.
Expert Opinion on Drug Safety|December 5, 2024
Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS databaseMin Chen, Yaping Huang, Chengjie Ke, et al.
Frontiers in Oncology|August 12, 2025
Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) databaseHuiling Zhang, Yaping Huang, Chengjie Ke, et al.
BMC Infectious Diseases|June 11, 2024
Impact of P2Y12 inhibitors on clinical outcomes in sepsis-3 patients receiving aspirin: a propensity score matched analysisShaojun Jiang, Jianwen Xu, Chengjie Ke, et al.
International Journal of Cancer|September 21, 2024
Postmarketing adverse events of tamoxifen in male and female patients with breast cancerChengjie Ke, Maohua Chen, Li Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|September 29, 2024
Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance studyMaohua Chen, Yaping Huang, Shaojun Jiang, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Immunopharmacology and Immunotoxicology|March 23, 2026
Comprehensive Pharmacovigilance Analysis of Lebrikizumab: A Real-World Safety Assessment Based on the FDA Adverse Event Reporting System (FAERS) DatabaseMaohua Chen, Chengjie Ke, Yaping Huang
The Journal of Dermatology|July 27, 2025
Safety Assessment of Ritlecitinib Based on the FDA Adverse Event Reporting System (FAERS) Database: A Real-World Pharmacovigilance StudyYaping Huang, Chengjie Ke, Maohua Chen
Dermatitis : Contact, Atopic, Occupational, Drug|November 18, 2025
Disproportionality Analysis of Nemolizumab in Patients with Atopic Dermatitis: A Real-World Pharmacovigilance StudyMaohua Chen, Chengjie Ke, Yaping Huang
Diagnostic Microbiology and Infectious Disease|September 28, 2024
Herpes virus reactivation induced by abrocitinib: A real-world pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) databaseMaohua Chen, Chengjie Ke, Yaping Huang
Inflammopharmacology|February 6, 2026
Postmarketing adverse events of biologics and Janus kinase inhibitors in patients with atopic dermatitisYaping Huang, Qing Zhou, Chengjie Ke, et al.
Expert Opinion on Drug Safety|December 5, 2024
Safety assessment of tafamidis: a real-world adverse event analysis from the FAERS databaseMin Chen, Yaping Huang, Chengjie Ke, et al.
Frontiers in Oncology|August 12, 2025
Disproportionality analysis of adverse events associated with pacritinib: a real-world study based on FDA Adverse Event Reporting System (FAERS) databaseHuiling Zhang, Yaping Huang, Chengjie Ke, et al.
BMC Infectious Diseases|June 11, 2024
Impact of P2Y12 inhibitors on clinical outcomes in sepsis-3 patients receiving aspirin: a propensity score matched analysisShaojun Jiang, Jianwen Xu, Chengjie Ke, et al.
International Journal of Cancer|September 21, 2024
Postmarketing adverse events of tamoxifen in male and female patients with breast cancerChengjie Ke, Maohua Chen, Li Lin, et al.
Lung Cancer (Amsterdam, Netherlands)|September 29, 2024
Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance studyMaohua Chen, Yaping Huang, Shaojun Jiang, et al.
Pageof 3